GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lombard Medical Technologies PLC (LSE:LMT) » Definitions » COGS-to-Revenue

Lombard Medical Technologies (LSE:LMT) COGS-to-Revenue : 0.64 (As of Dec. 2012)


View and export this data going back to . Start your Free Trial

What is Lombard Medical Technologies COGS-to-Revenue?

Lombard Medical Technologies's Cost of Goods Sold for the six months ended in Dec. 2012 was £2.49 Mil. Its Revenue for the six months ended in Dec. 2012 was £3.89 Mil.

Lombard Medical Technologies's COGS to Revenue for the six months ended in Dec. 2012 was 0.64.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lombard Medical Technologies's Gross Margin % for the six months ended in Dec. 2012 was 35.99%.


Lombard Medical Technologies COGS-to-Revenue Historical Data

The historical data trend for Lombard Medical Technologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lombard Medical Technologies COGS-to-Revenue Chart

Lombard Medical Technologies Annual Data
Trend Sep02 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.58 0.54 0.51 0.64

Lombard Medical Technologies Semi-Annual Data
Sep02 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.58 0.54 0.51 0.64

Lombard Medical Technologies COGS-to-Revenue Calculation

Lombard Medical Technologies's COGS to Revenue for the fiscal year that ended in Dec. 2012 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.49 / 3.89
=0.64

Lombard Medical Technologies's COGS to Revenue for the quarter that ended in Dec. 2012 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.49 / 3.89
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lombard Medical Technologies  (LSE:LMT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lombard Medical Technologies's Gross Margin % for the six months ended in Dec. 2012 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2.49 / 3.89
=35.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Lombard Medical Technologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lombard Medical Technologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lombard Medical Technologies (LSE:LMT) Business Description

Traded in Other Exchanges
N/A
Address
Lombard Medical Technologies PLC is engaged in the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through the group's own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. The principal product, the AorfixT AAA stent graft has European CE mark approval for use in patients with high-angle-neck aneurysms of up to 90 degrees. The group has operations in United Kingdom and United States of America.